Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
iSpecimen ( (ISPC) ) has shared an announcement.
iSpecimen Inc. has appointed Robert Lim as its new CEO and member of the Board of Directors, effective December 9, 2024. Lim brings extensive experience in the pharmaceutical and biotechnology industries, alongside a strong legal and marketing background, positioning him to lead iSpecimen in achieving its strategic objectives and enhancing profitability. This leadership change is expected to impact the company’s operations and industry positioning, potentially driving sustainable growth and uncovering untapped business opportunities.
More about iSpecimen
iSpecimen Inc. operates an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers. It uses proprietary, cloud-based technology to facilitate the search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations.
YTD Price Performance: -65.23%
Average Trading Volume: 434,282
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.35M
Learn more about ISPC stock on TipRanks’ Stock Analysis page.
